{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:09Z","timestamp":1792787289223,"version":"4.5.0"},"reference-count":53,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"\u201cAidsfonds\u201d Netherlands","award":["2008.026"],"award-info":[{"award-number":["2008.026"]}]},{"name":"\u201cAidsfonds\u201d Netherlands","award":["2013.037"],"award-info":[{"award-number":["2013.037"]}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["015.015.042"],"award-info":[{"award-number":["015.015.042"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["91719372"],"award-info":[{"award-number":["91719372"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Amsterdam UMC","award":["2017"],"award-info":[{"award-number":["2017"]}],"id":[{"id":"https:\/\/ror.org\/05grdyy37","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Without a vaccine, HCV (re)infections continue to afflict individuals at high risk, for example, men who have sex with men (MSM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To guide vaccine development, we assessed whether natural protection against observed HCV reinfection among MSM was associated with a distinct humoral immune profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      From a prospective cohort of HIV-positive MSM with acute HCV infection (MOSAIC, Dutch MSM Observational Study of Acute Infection with hepatitis C), we selected 13 cases who became HCV-reinfected (R) and 18 controls who remained free of observed reinfections (non-reinfected, NR) in 0.5\u20139.5 years after primary infection clearance, matched for calendar year of primary infection. At time point T\n                      <jats:sub>1<\/jats:sub>\n                      (29 days before to 78 days after primary clearance) and T\n                      <jats:sub>2<\/jats:sub>\n                      (3\u20136 months before R subjects\u2019 first reinfection), we evaluated serum antibody responses against HCV\u2019s E1E2 envelope glycoprotein. Based solely on E1E2-binding antibody levels and Fc-gamma receptor (Fc\u03b3R)\/C1q engagement at T\n                      <jats:sub>1<\/jats:sub>\n                      , we divided participants into subgroups using latent profile analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HCV-neutralising responses were observed mainly at T\n                      <jats:sub>1<\/jats:sub>\n                      (9\/18 NR and 3\/13 R participants). The NR group could be distinguished from the R group at T\n                      <jats:sub>1<\/jats:sub>\n                      by higher levels of E1E2-binding antibodies that bound Fc\u03b3Rs\/C1q. Among four identified latent profiles, HCV reinfection prevalence was lowest in the profile defined by moderate to high levels of E1E2-binding antibodies (IgM\/IgG\/IgG1\/IgG3) and Fc\u03b3R\/C1q engagement. This profile exhibited a relatively broad, potent HCV-neutralising capacity and the broadest epitope specificity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We propose broad, potent serum Fc-mediated effector functions and neutralisation and a broad anti-E1E2 antibody epitope specificity as ingredients of HCV-protective immunity towards which vaccination approaches should aim.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2025-336302","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:05:23Z","timestamp":1761289523000},"page":"2256-2266","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort"],"prefix":"10.1136","volume":"75","author":[{"given":"Ana Luz","family":"Chumbe","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands"},{"name":"Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9262-7322","authenticated-orcid":false,"given":"Suzanne M D","family":"van den Aardweg","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands"},{"name":"Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Boyd","sequence":"additional","affiliation":[{"name":"Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands"},{"name":"Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, Netherlands"},{"name":"Stichting HIV Monitoring, Amsterdam, Netherlands"},{"name":"Department of Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"Grobben","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands"},{"name":"Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie M","family":"Koekkoek","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands"},{"name":"Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Zon","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands"},{"name":"Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prins","sequence":"additional","affiliation":[{"name":"Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands"},{"name":"Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, Netherlands"},{"name":"Department of Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwinten","family":"Sliepen","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands"},{"name":"Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit J","family":"van Gils","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands"},{"name":"Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janke","family":"Schinkel","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands"},{"name":"Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"2026100702350683000_75.11.2256.1","unstructured":"WHO . Global hepatitis report 2024: Action for access in low- and middle-income countries. Report no.: 978-92-4-009167-2. 2024."},{"key":"2026100702350683000_75.11.2256.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00651.x"},{"key":"2026100702350683000_75.11.2256.3","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1111\/liv.15705","article-title":"Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis","volume":"43","author":"Munari","year":"2023","journal-title":"Liver Int"},{"key":"2026100702350683000_75.11.2256.4","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/hep.31182","article-title":"Hepatitis C Vaccine: 10 Good Reasons for Continuing","volume":"71","author":"Roingeard","year":"2020","journal-title":"Hepatology"},{"key":"2026100702350683000_75.11.2256.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1411-9","article-title":"The case for a universal hepatitis C vaccine to achieve hepatitis C elimination","volume":"17","author":"Scott","year":"2019","journal-title":"BMC Med"},{"key":"2026100702350683000_75.11.2256.6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jhep.2020.09.022","article-title":"T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine","volume":"74","author":"Thimme","year":"2021","journal-title":"J Hepatol"},{"key":"2026100702350683000_75.11.2256.7","doi-asserted-by":"publisher","DOI":"10.1038\/nm1698"},{"key":"2026100702350683000_75.11.2256.8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1114927109"},{"key":"2026100702350683000_75.11.2256.9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009512","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"de Jong","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026100702350683000_75.11.2256.10","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24344"},{"key":"2026100702350683000_75.11.2256.11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28850"},{"key":"2026100702350683000_75.11.2256.12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28428"},{"key":"2026100702350683000_75.11.2256.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.10.015"},{"key":"2026100702350683000_75.11.2256.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274283","article-title":"Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants","volume":"17","author":"Yokokawa","year":"2022","journal-title":"PLoS One"},{"key":"2026100702350683000_75.11.2256.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607026104"},{"key":"2026100702350683000_75.11.2256.16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27013"},{"key":"2026100702350683000_75.11.2256.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.10.012"},{"key":"2026100702350683000_75.11.2256.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002895","article-title":"Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees","volume":"8","author":"Morin","year":"2012","journal-title":"PLoS Pathog"},{"key":"2026100702350683000_75.11.2256.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402458101"},{"key":"2026100702350683000_75.11.2256.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.004"},{"key":"2026100702350683000_75.11.2256.21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1403769","article-title":"Coordinated expansion of memory T follicular helper and B cells mediates spontaneous clearance of HCV reinfection","volume":"15","author":"Eisa","year":"2024","journal-title":"Front Immunol"},{"key":"2026100702350683000_75.11.2256.22","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.106"},{"key":"2026100702350683000_75.11.2256.23","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13393"},{"key":"2026100702350683000_75.11.2256.24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84428"},{"key":"2026100702350683000_75.11.2256.25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae241"},{"key":"2026100702350683000_75.11.2256.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005578","article-title":"Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection","volume":"12","author":"Tan","year":"2016","journal-title":"PLoS Pathog"},{"key":"2026100702350683000_75.11.2256.27","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284"},{"key":"2026100702350683000_75.11.2256.28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-021-04017-w","article-title":"Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy","volume":"599","author":"Yamin","year":"2021","journal-title":"Nature New Biol"},{"key":"2026100702350683000_75.11.2256.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.11.006"},{"key":"2026100702350683000_75.11.2256.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.11.012"},{"key":"2026100702350683000_75.11.2256.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012739","article-title":"Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression","volume":"20","author":"Grobben","year":"2024","journal-title":"PLoS Pathog"},{"key":"2026100702350683000_75.11.2256.32","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/HEP.0000000000000753","article-title":"Concerted synergy between viral-specific IgG and CD8 + T cells is critical for clearance of an HCV-related rodent hepacivirus","volume":"80","author":"Gridley","year":"2024","journal-title":"Hepatology"},{"key":"2026100702350683000_75.11.2256.33","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29381","article-title":"Characterization of antibody-dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes","volume":"96","author":"Adhikari","year":"2024","journal-title":"J Med Virol"},{"key":"2026100702350683000_75.11.2256.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.12.018"},{"key":"2026100702350683000_75.11.2256.35","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283480144"},{"key":"2026100702350683000_75.11.2256.36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/cid\/ciaa645","article-title":"Incidence of HCV Reinfection Among HIV-Positive MSM and Its Association With Sexual Risk Behavior: A Longitudinal Analysis","volume":"73","author":"Newsum","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026100702350683000_75.11.2256.37","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv115","article-title":"Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study","volume":"2","author":"Vanhommerig","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2026100702350683000_75.11.2256.38","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2024.199308","article-title":"A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns","volume":"341","author":"Chumbe","year":"2024","journal-title":"Virus Res"},{"key":"2026100702350683000_75.11.2256.39","unstructured":"Parham P . The Immune System. 5th edn. New York, NY: W.W. Norton & Company, 2021."},{"key":"2026100702350683000_75.11.2256.40","doi-asserted-by":"crossref","unstructured":"Bauer J . A primer to latent profile and latent class analysis. In: Goller M , Kyndt E , Paloniemi S , et al ., eds. Methods for Researching Professional Learning and Development: Challenges, Applications and Empirical Illustrations. Cham: Springer International Publishing, 2022: 243\u201368.","DOI":"10.1007\/978-3-031-08518-5_11"},{"key":"2026100702350683000_75.11.2256.41","doi-asserted-by":"crossref","first-page":"113766","DOI":"10.1016\/j.jim.2024.113766","article-title":"The mouse monoclonal antibody 4E3 is specific for the G1m17 allotype of human IgG1","volume":"534","author":"Mov\u00e9rare","year":"2024","journal-title":"J Immunol Methods"},{"key":"2026100702350683000_75.11.2256.42","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1494","article-title":"Immunoglobulin G genetic variation can confound assessment of antibody levels via altered binding to detection reagents","volume":"13","author":"Purcell","year":"2024","journal-title":"Clin Transl Immunology"},{"key":"2026100702350683000_75.11.2256.43","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jhep.2019.11.011","article-title":"B cell immunodominance in primary hepatitis C virus infection","volume":"72","author":"Brasher","year":"2020","journal-title":"J Hepatol"},{"key":"2026100702350683000_75.11.2256.44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.17.11095-11104.2005"},{"key":"2026100702350683000_75.11.2256.45","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39659-z","article-title":"Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies","volume":"14","author":"Metcalf","year":"2023","journal-title":"Nat Commun"},{"key":"2026100702350683000_75.11.2256.46","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01032-17","article-title":"Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope","volume":"91","author":"Pierce","year":"2017","journal-title":"J Virol"},{"key":"2026100702350683000_75.11.2256.47","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020294","article-title":"Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency","volume":"8","author":"Czarnota","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2026100702350683000_75.11.2256.48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-78049-3","article-title":"Minicircle-based vaccine induces potent T-cell and antibody responses against hepatitis C virus","volume":"14","author":"Czarnota","year":"2024","journal-title":"Sci Rep"},{"key":"2026100702350683000_75.11.2256.49","doi-asserted-by":"crossref","DOI":"10.1186\/s12934-016-0460-4","article-title":"Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus","volume":"15","author":"Czarnota","year":"2016","journal-title":"Microb Cell Fact"},{"key":"2026100702350683000_75.11.2256.50","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado2600","article-title":"Epitope-focused immunogens targeting the hepatitis C virus glycoproteins induce broadly neutralizing antibodies","volume":"10","author":"Nagarathinam","year":"2024","journal-title":"Sci Adv"},{"key":"2026100702350683000_75.11.2256.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01040-6"},{"key":"2026100702350683000_75.11.2256.52","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33035-z","article-title":"Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C","volume":"13","author":"Nishio","year":"2022","journal-title":"Nat Commun"},{"key":"2026100702350683000_75.11.2256.53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0326094","article-title":"Longitudinal trajectories of sexual behavior and incident hepatitis C reinfection among men who have sex with men with HIV","volume":"20","author":"Hage","year":"2025","journal-title":"PLoS One"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2025-336302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:35:35Z","timestamp":1791365735000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2025-336302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,10,7]]},"published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1136\/gutjnl-2025-336302"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2025-336302","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}